Literature DB >> 6794969

The artifactual nature of heparin-induced drug protein-binding alterations.

J E Brown, B B Kitchell, T D Bjornsson, D G Shand.   

Abstract

Our purpose was to determine whether the reported alteration of protein drug binding after heparin administration in man was artifactual as a result of continued in vitro activity of triglyceride lipases. The lipoprotein lipase inhibitors protamine (14 mg/ml) and ethylenediaminetetraacetic acid (10 mg/ml) were added to blood samples from 11 healthy subjects before and 15 min after 100 USP units of intravenous heparin. Heparin elevated total nonesterified fatty acid (NEFA) concentration (P less than 0.001) and free fractions of lidocaine, diazepam, and propranolol (P less than 0.001 for all). The presence of the lipase inhibitors diminished the heparin-induced elevation of NEFA (P less than 0.001) and free fractions of lidocaine (P less than 0.001) and diazepam (P less than 0.001), but these values were still greater than control. The inhibitors reduced propranolol binding in control samples and did not diminish the effects of heparin. The change in NEFA concentrations correlated with the free fraction changes of all three ligands (r = 0.739 to 0.849). These data suggest that the heparin-induced protein binding changes are to, a large extent, in vitro artifacts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6794969     DOI: 10.1038/clpt.1981.215

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

2.  Potential applications of free drug level monitoring in cardiovascular therapy.

Authors:  R L Woosley; L A Siddoway; K Thompson; I Cerskus; D M Roden
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 3.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

4.  alpha 1-Acid glycoprotein and plasma lidocaine binding.

Authors:  D G Shand
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

5.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

6.  Inhibitory effect of free fatty acids on plasma protein binding of disopyramide in haemodialysis patients.

Authors:  T Horiuchi; I Johno; T Hasegawa; S Kitazawa; M Goto; T Hata
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Determinants of the plasma protein binding of theophylline in health.

Authors:  D Buss; D Leopold; A P Smith; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 9.  Pharmacokinetic drug interactions with propranolol.

Authors:  A J Wood; J Feely
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.